Liraglutide Long-Term Safety Data

Liraglutide

9,340 patients

The LEADER trial followed 9,340 patients with type 2 diabetes for a median of 3.8 years, demonstrating a 13% reduction in major cardiovascular events with liraglutide.

Marso et al., New England Journal of Medicine, 2016

Marso et al., New England Journal of Medicine, 2016

View as image

Liraglutide has been on the market since 2010, first as Victoza (1.2-1.8 mg for type 2 diabetes) and then as Saxenda (3.0 mg for weight management, approved 2014). That is over 15 years of prescribing data, multiple cardiovascular outcome trials, and millions of patient-years of real-world exposure. The safety picture that has emerged is nuanced: clear cardiovascular benefits, a persistent but small thyroid cancer signal, manageable GI side effects, and no confirmed increase in pancreatitis. For a broader comparison of where liraglutide fits among newer GLP-1 drugs, see our dedicated article.

The LEADER Trial: 3.8 Years of Cardiovascular Data

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial remains the definitive long-term safety dataset for liraglutide.^[1] This double-blind, randomized trial enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk across 32 countries. Patients received liraglutide (up to 1.8 mg daily) or placebo on top of standard care. The median follow-up was 3.8 years, with a maximum of 5 years.

The primary composite outcome (first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 13.0% of liraglutide patients versus 14.9% of placebo patients (HR 0.87, 95% CI 0.78-0.97, P=0.01 for superiority).^[1]

Breaking down the components:

• Cardiovascular death: 4.7% vs. 6.0% (HR 0.78, P=0.007)
• Death from any cause: 8.2% vs. 9.6% (HR 0.85, P=0.02)
• Nonfatal myocardial infarction: Nonsignificantly lower with liraglutide
• Nonfatal stroke: Nonsignificantly lower with liraglutide
• Hospitalization for heart failure: Nonsignificantly lower with liraglutide

The cardiovascular death reduction was the primary driver of the overall benefit. This finding changed clinical practice: liraglutide received an FDA indication for reducing cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease, a use beyond glucose control.

Rizzo et al. (2014) provided mechanistic support for these cardiovascular benefits in an earlier 8-month prospective study. Liraglutide treatment decreased carotid intima-media thickness (a marker of atherosclerosis progression) in patients with type 2 diabetes, suggesting direct vascular protective effects that preceded the LEADER trial's clinical outcome data.^[2]

Pancreatitis: The Fear That Data Did Not Confirm

Early case reports of acute pancreatitis in GLP-1 receptor agonist users prompted an FDA safety review and generated widespread concern. The LEADER trial was powered to address this question with statistical rigor.

The results were reassuring: acute pancreatitis occurred in 18 liraglutide patients (0.4%) versus 23 placebo patients (0.5%).^[1] Numerically, there were fewer cases of pancreatitis in the liraglutide group than in the placebo group. The difference was not statistically significant in either direction, but the absence of any signal in nearly 10,000 patients followed for nearly 4 years substantially downgraded the concern.

Pancreatic cancer showed a different pattern: 13 cases in the liraglutide group versus 5 in the placebo group. This numerical imbalance was not statistically significant given the small total numbers, and it could reflect detection bias (patients on liraglutide may have had more frequent medical monitoring). No overall difference in cancer rates was observed between groups. Post-marketing surveillance has not identified a clear causal association between liraglutide and pancreatic cancer.

Thyroid Cancer: A Small Signal That Persists

GLP-1 receptor agonists cause dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rodents. This class effect prompted a black box warning on all GLP-1 RA labels and contraindication in patients with personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN 2).

In the LEADER trial, medullary thyroid carcinoma occurred in zero liraglutide patients and one placebo patient.^[1] This provided some reassurance, but the trial was not designed to detect rare cancers.

Silverii et al. (2024) conducted a systematic review and meta-analysis of 64 randomized controlled trials, 26 of which reported at least one case of thyroid cancer.^[4] GLP-1 RA treatment was associated with a statistically significant increase in overall thyroid cancer risk (MH-OR 1.52, 95% CI 1.01-2.29, P=0.04). The finding had a fragility index of 1, meaning a single additional event would have made it non-significant. The 5-year number needed to harm was 1,349, meaning roughly 1,350 patients would need to be treated for 5 years for one additional thyroid cancer case to occur.^[4]

The association was not significant for specific thyroid cancer subtypes: papillary thyroid cancer (MH-OR 1.54, P=0.22) and medullary thyroid cancer (MH-OR 1.44, P=0.55).^[4] Whether the overall signal reflects a true biological effect or detection bias remains debated. Liraglutide prescribing does not involve routine thyroid cancer screening, but patients on GLP-1 RAs may receive more medical attention overall, potentially leading to incidental thyroid cancer detection. For a deeper dive into this question, see our article on GLP-1 agonists and thyroid cancer risk.

Gastrointestinal Side Effects: Common but Usually Temporary

The most consistent adverse effect of liraglutide is gastrointestinal (GI) distress. In the LEADER trial, GI events were the most common reason patients discontinued liraglutide.^[1] Across liraglutide clinical trials:

• Nausea: 20-40% of patients, typically peaking in the first 2-4 weeks and resolving by 8-12 weeks
• Diarrhea: 10-15% of patients
• Vomiting: 5-10% of patients
• Constipation: 5-10% of patients

The standard mitigation strategy is slow dose titration: starting at 0.6 mg daily and increasing by 0.6 mg weekly to the target dose. This reduces (but does not eliminate) nausea. At the 3.0 mg weight management dose (Saxenda), GI side effects are more common than at the 1.2-1.8 mg diabetes doses (Victoza).

GI side effects contribute to weight loss but are not the primary mechanism. Liraglutide's weight effects are mediated primarily through hypothalamic appetite suppression and delayed gastric emptying, not through nausea-induced food aversion.

Safety in Adolescents

Danne et al. (2017) conducted the first randomized, double-blind, placebo-controlled trial of liraglutide in adolescents aged 12-17 with obesity.^[3] Twenty-one subjects were randomized. The 5-week trial assessed safety, tolerability, and pharmacokinetics rather than efficacy.

Liraglutide showed a similar safety and tolerability profile in adolescents compared to adults, with no unexpected adverse events.^[3] Pharmacokinetic parameters were consistent with adult data, supporting the use of the same dosing approach. This trial laid the groundwork for the subsequent Phase 3 pediatric obesity trials that led to liraglutide's approval for adolescent obesity.

The pediatric safety question remains important because children and adolescents would potentially use these drugs for decades. Long-term follow-up data in this age group is limited, and the thyroid C-cell signal in rodents is particularly relevant given the developing nature of adolescent endocrine systems.

What Happens When You Stop

Weight regain after liraglutide discontinuation is well-documented and substantial. In the SCALE Maintenance trial, patients who discontinued liraglutide after initial weight loss regained roughly two-thirds of their lost weight over the following year. This is consistent across GLP-1 receptor agonists and reflects the fact that these drugs treat the symptoms (excess appetite, insufficient satiety signaling) rather than the underlying neurobiology of obesity.

For type 2 diabetes, discontinuation leads to return of HbA1c to pre-treatment levels within months. The cardiovascular protective effects observed in LEADER likely do not persist after stopping treatment, though this has not been specifically studied.

This discontinuation effect is not unique to liraglutide. It is a class property of GLP-1 receptor agonists and has implications for treatment duration, cost-effectiveness, and patient expectations. Newer GLP-1 drugs like semaglutide show similar rebound patterns.

Other Safety Signals

Gallbladder events. GLP-1 receptor agonists, including liraglutide, are associated with increased risk of cholelithiasis (gallstones) and cholecystitis. This is partly attributable to rapid weight loss (a known risk factor for gallstones) and partly to direct effects on gallbladder motility. In LEADER, gallbladder-related events were more common with liraglutide than placebo. For more on this issue, see GLP-1s and gallbladder problems.

Injection site reactions. At the 1.2-1.8 mg doses, injection site reactions are uncommon. At 3.0 mg, they occur in approximately 2-5% of patients. Reactions are typically mild and do not require discontinuation.

Heart rate increase. Liraglutide increases resting heart rate by an average of 2-3 beats per minute. The mechanism is not fully understood but may involve direct GLP-1 receptor effects on the sinoatrial node. In LEADER, this heart rate increase did not translate to adverse cardiovascular outcomes (in fact, outcomes were better with liraglutide), but it remains a monitoring consideration.

Hypoglycemia. When used as monotherapy or with metformin, liraglutide carries low risk of hypoglycemia. When combined with sulfonylureas or insulin, the risk increases substantially, and dose reduction of the sulfonylurea or insulin is typically required.

The Bottom Line

Liraglutide's safety profile after 15+ years of clinical use shows clear cardiovascular benefits (13% reduction in MACE, 22% reduction in CV death in LEADER), no confirmed pancreatitis signal, a small but statistically significant thyroid cancer signal (OR 1.52 with NNH of 1,349), and common but usually transient GI side effects. The adolescent safety profile mirrors adult data. The main long-term concern beyond thyroid cancer is weight regain upon discontinuation, which is a class-wide property of GLP-1 receptor agonists rather than specific to liraglutide.

Frequently Asked Questions

Is liraglutide safe for long-term use?

The LEADER trial followed 9,340 patients for a median of 3.8 years and found liraglutide reduced cardiovascular events by 13% and cardiovascular death by 22% compared to placebo. Pancreatitis rates were similar between groups (0.4% vs 0.5%). The main long-term concerns are a small thyroid cancer signal, bone density effects at the 3.0 mg dose, and GI side effects that typically resolve within weeks.^[1]

Does liraglutide cause thyroid cancer?

In rodents, GLP-1 receptor agonists cause thyroid C-cell tumors. In humans, a meta-analysis of 64 RCTs found a modest increase in thyroid cancer risk (OR 1.52), but with a fragility index of 1 and a 5-year number needed to harm of 1,349. The LEADER trial found zero cases of medullary thyroid carcinoma in 4,668 liraglutide patients. The signal is too small to confirm or rule out a causal relationship.^[4]

Does liraglutide cause pancreatitis?

In the LEADER trial (9,340 patients, 3.8 years), acute pancreatitis occurred in 0.4% of liraglutide patients vs. 0.5% of placebo patients. There were numerically fewer pancreatitis cases with liraglutide than placebo. This large, long-term dataset substantially reduced early concerns about a GLP-1 RA-pancreatitis link.^[1]

What are the most common side effects of liraglutide?

Gastrointestinal effects are most common: nausea (20-40% initially), diarrhea (10-15%), vomiting (5-10%), and constipation (5-10%). These typically peak in the first 2-4 weeks and resolve by 8-12 weeks. Slow dose titration (starting at 0.6 mg, increasing weekly by 0.6 mg) reduces severity. GI events are the most common reason for discontinuation.^[1]

Is liraglutide safe for teenagers?

A randomized trial in 21 adolescents aged 12-17 with obesity found liraglutide had a similar safety and tolerability profile to adults, with no unexpected adverse events. Pharmacokinetics were consistent with adult data. Long-term pediatric safety data is limited, and the thyroid C-cell signal observed in rodents remains a theoretical concern for developing endocrine systems.^[3]

What happens when you stop taking liraglutide?

Weight regain after liraglutide discontinuation is substantial. In clinical trials, patients regained roughly two-thirds of their lost weight within a year of stopping. For type 2 diabetes, HbA1c returns to pre-treatment levels within months. The cardiovascular benefits observed in LEADER likely do not persist after stopping. This rebound effect is common to all GLP-1 receptor agonists, not just liraglutide.